Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CDXS 
Codexis Inc (CDXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CDXS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.08
1 Year Target Price $7.08
| 4 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.29% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 224.77M USD | Price to earnings Ratio - | 1Y Target Price 7.08 |
Price to earnings Ratio - | 1Y Target Price 7.08 | ||
Volume (30-day avg) 7 | Beta 2.54 | 52 Weeks Range 1.90 - 6.08 | Updated Date 09/17/2025 |
52 Weeks Range 1.90 - 6.08 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -113.67% | Operating Margin (TTM) -83.91% |
Management Effectiveness
Return on Assets (TTM) -26.48% | Return on Equity (TTM) -111% |
Valuation
Trailing PE - | Forward PE 138.89 | Enterprise Value 222902612 | Price to Sales(TTM) 3.93 |
Enterprise Value 222902612 | Price to Sales(TTM) 3.93 | ||
Enterprise Value to Revenue 3.9 | Enterprise Value to EBITDA -10.67 | Shares Outstanding 90267504 | Shares Floating 68485925 |
Shares Outstanding 90267504 | Shares Floating 68485925 | ||
Percent Insiders 2.28 | Percent Institutions 80.74 |
Upturn AI SWOT
Codexis Inc
Company Overview
History and Background
Codexis, Inc. was founded in 2002. It is a protein engineering company that develops and sells enzymes. It initially focused on biofuels but has expanded to pharmaceuticals, food, and other markets.
Core Business Areas
- Performance Enzymes: Codexis develops and sells enzymes used in pharmaceutical manufacturing, food production, and other industrial processes. This is their core revenue driver.
- Novel Biotherapeutics: Codexis also engages in research and development of novel biotherapeutics leveraging its enzyme engineering capabilities. This is a longer-term growth area.
Leadership and Structure
Stephen Dilly serves as the President and CEO. The company has a board of directors overseeing strategic decisions. Codexis operates with a functional organizational structure, with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Codex HiCapu2122: A polymerase that enables the enzymatic synthesis of DNA molecules. It is used in pharmaceutical manufacturing. Market share is difficult to ascertain precisely, but Codexis is considered a leader in enzyme engineering. Competitors include companies offering similar enzyme engineering services and alternative manufacturing processes (e.g., chemical synthesis).
- EvolvRu2122: A protein engineering platform that enables the creation of high-performing enzymes. This platform is a key revenue driver. Competition includes other protein engineering firms and companies that offer alternative enzyme design technologies.
Market Dynamics
Industry Overview
The enzyme engineering market is growing, driven by the increasing demand for sustainable and efficient manufacturing processes in pharmaceuticals, food, and other industries. Key trends include the development of more robust and specific enzymes, as well as the use of AI and machine learning in enzyme design.
Positioning
Codexis is positioned as a leader in enzyme engineering, with a strong technology platform and a track record of developing successful enzymes for a variety of applications. Its competitive advantages include its proprietary enzyme evolution technology and its expertise in enzyme engineering.
Total Addressable Market (TAM)
The TAM for enzyme engineering is estimated to be in the billions of dollars and is expected to continue to grow. Codexis is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Strong enzyme engineering platform
- Expertise in protein engineering
- Track record of developing successful enzymes
- Established customer base
Weaknesses
- Reliance on key customers
- Competition from other enzyme engineering companies
- Dependence on research and development success
- Relatively small market capitalization compared to large pharma partners
Opportunities
- Expanding into new markets, such as food and biotherapeutics
- Developing new enzyme applications
- Acquiring complementary technologies
- Collaborating with pharmaceutical companies
Threats
- Competition from other enzyme engineering companies
- Development of alternative technologies
- Regulatory hurdles
- Economic downturns
Competitors and Market Share
Key Competitors
- NOVO
- DANISCO
- DSM
Competitive Landscape
Codexis competes with other enzyme engineering companies, as well as companies that offer alternative manufacturing processes. Codexis differentiates itself through its proprietary enzyme evolution technology and its expertise in enzyme engineering.
Major Acquisitions
Muse Bio
- Year: 2023
- Acquisition Price (USD millions): 150
- Strategic Rationale: Extends its biofoundry capabilities and its capabilities in synthetic biology.
Growth Trajectory and Initiatives
Historical Growth: Codexis has experienced revenue growth driven by increased demand for its enzyme engineering services and products. The company has expanded into new markets and applications, contributing to its growth.
Future Projections: Analysts project continued revenue growth for Codexis, driven by its strong technology platform and its expansion into new markets. Expected increases will be driven by the biotherapeutics sector.
Recent Initiatives: Recent initiatives include expansion in new markets, as well as R&D investments for novel enzyme development.
Summary
Codexis shows significant promise within the enzyme engineering field thanks to its proprietary technologies. The company has been growing its biopharma footprint as well as increasing revenues, albeit with inconsistent net income. It needs to continue to focus on scaling revenues while maintaining costs and ensuring long term product development. The overall direction of the company appears stable and promising.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Codexis Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2010-04-22 | President, CEO & Chairman Dr. Stephen George Dilly MBBS, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 188 | Website https://www.codexis.com |
Full time employees 188 | Website https://www.codexis.com | ||
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.